Market Closed -
Japan Exchange
02:00:00 2024-05-31 am EDT
|
5-day change
|
1st Jan Change
|
325
JPY
|
+5.18%
|
|
-0.61%
|
-47.41%
|
Fiscal Period: March |
2022
|
2023
|
---|
Capitalization
1 |
4,892
|
3,504
|
Enterprise Value (EV)
1 |
1,678
|
1,060
|
P/E ratio
|
-7.64
x
|
-4.46
x
|
Yield
|
-
|
-
|
Capitalization / Revenue
|
68.9
x
|
37.3
x
|
EV / Revenue
|
23.6
x
|
11.3
x
|
EV / EBITDA
|
-3,562,442
x
|
-1,532,207
x
|
EV / FCF
|
-6,721,724
x
|
-1,678,666
x
|
FCF Yield
|
-0%
|
-0%
|
Price to Book
|
1.55
x
|
1.46
x
|
Nbr of stocks (in thousands)
|
11,759
|
11,759
|
Reference price
2 |
416.0
|
298.0
|
Announcement Date
|
6/23/22
|
6/23/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
303
|
275
|
85
|
67
|
71
|
94
|
EBITDA
|
-
|
-
|
-
|
-
|
-471
|
-692
|
EBIT
1 |
-166
|
-145
|
-812
|
-411
|
-473
|
-697
|
Operating Margin
|
-54.79%
|
-52.73%
|
-955.29%
|
-613.43%
|
-666.2%
|
-741.49%
|
Earnings before Tax (EBT)
1 |
-177
|
-162
|
-840
|
-412
|
-598
|
-785
|
Net income
1 |
-178
|
-163
|
-841
|
-413
|
-599
|
-786
|
Net margin
|
-58.75%
|
-59.27%
|
-989.41%
|
-616.42%
|
-843.66%
|
-836.17%
|
EPS
2 |
-68.97
|
-26.52
|
-136.8
|
-59.00
|
-54.47
|
-66.84
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-249.6
|
-631.6
|
FCF margin
|
-
|
-
|
-
|
-
|
-351.58%
|
-671.94%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/17/20
|
2/17/20
|
5/19/21
|
5/19/21
|
6/23/22
|
6/23/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
1,449
|
1,100
|
482
|
1,069
|
3,214
|
2,444
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-250
|
-632
|
ROE (net income / shareholders' equity)
|
-
|
-11.6%
|
-92.8%
|
-52.7%
|
-28.3%
|
-28.3%
|
ROA (Net income/ Total Assets)
|
-
|
-6.31%
|
-53.2%
|
-30.9%
|
-13.4%
|
-14.9%
|
Assets
1 |
-
|
2,585
|
1,580
|
1,338
|
4,476
|
5,292
|
Book Value Per Share
2 |
577.0
|
216.0
|
78.90
|
130.0
|
268.0
|
204.0
|
Cash Flow per Share
2 |
561.0
|
179.0
|
78.40
|
128.0
|
274.0
|
208.0
|
Capex
|
-
|
-
|
-
|
-
|
33
|
164
|
Capex / Sales
|
-
|
-
|
-
|
-
|
46.48%
|
174.47%
|
Announcement Date
|
2/17/20
|
2/17/20
|
5/19/21
|
5/19/21
|
6/23/22
|
6/23/23
|
|
1st Jan change
|
Capi.
|
---|
| -47.41% | 25.48M | | -2.29% | 89.87B | | -3.95% | 37.57B | | -13.07% | 32.75B | | +63.05% | 26.47B | | -22.14% | 14.25B | | -7.96% | 12.99B | | -9.33% | 11.93B | | -46.33% | 10.84B | | +5.77% | 9.11B |
Biopharmaceuticals
|